SimCosmetic Biotech today announced that it has entered into joint Research Collaboration with Indena S.p.A. to explore novel biological activities of cosmetic ingredients.
SimCosmetic will use proprietary platforms SimDerma and INCOS to screen Indena´s cosmetic ingredients. SimDerma is a platform that includes 30 molecular and cellular targets of special relevance for the cosmetic market. SimDermawill define key biological activities to be further analyzed by INCOS (INgredient COmbinatorial System). INCOS implements an algorithm capable of calculating optimized ingredient blends for different applications, which include both the application originally requested by the customer as a series of sub-applications, which may emerge from the described combinations and are detected by the system.
SimCosmetic Biotech is a young company located at Scientific Park of Madrid (Madrid, Spain). This breakthrough project intended as a novel technological support to develop skin care products based on scientific knowledge from multiple disciplines, ongoing from in vitro cell cultures to computer simulation and bioinformatic approaches.
Indena is the leading company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health food and personal care industries. Backed up by 90 years of botanical experience, the key to Indena’s success is its intense research activity. The company has more than 150 primary patents and has published more than 700 scientific studies. Indena employs more than 800 staff, including 10% dedicated to full-time research activities carried out at Settala Research Center, near Milan. Indena also co-operates with the world’s most prestigious universities and private research institutions. Headquartered in Milan, Indena has 5 production sites and 4 international branches throughout the world and manages sales in more than 70 countries. The Company’s experts communicate and interact constantly with the major international regulatory authorities such as WHO, EMA, and ESCOP, and cooperate on the update of all the main pharmacopoeias.